Related Experiment Videos
[Persisting suppression of hyperprolactinemia after bromcriptine withdrawal]
Jugoslavenska Ginekologija I Opstetricija
|January 1, 1982
Summary
Parlodel effectively treated a patient with a pituitary macroprolactinoma, normalizing prolactin levels and restoring menstrual cycles. The patient later conceived and delivered a healthy baby without tumor growth.
Area of Science:
- Endocrinology
- Reproductive Medicine
Background:
- Macroprolactinoma, a pituitary tumor, can cause secondary amenorrhea and galactorrhea.
- Hyperprolactinemia is a common endocrine disorder associated with pituitary adenomas.
Purpose of the Study:
- To report the successful management of a patient with a pituitary macroprolactinoma using Parlodel (bromocriptine).
- To evaluate the efficacy of Parlodel in normalizing prolactin levels, restoring reproductive function, and managing tumor size.
Main Methods:
- A 22-year-old patient with secondary amenorrhea, galactorrhea, and pituitary macroprolactinoma was treated with Parlodel.
- Dosage was adjusted from 20 mg daily to 2.5 mg intermittently until ovulation.
Main Results:
- Treatment normalized prolactin levels and restored regular menstrual cycles within 34 months.
- The patient conceived 5 months after therapy cessation, with normal prolactin during pregnancy and no tumor growth.
- Post-lactation, hyperprolactinemia persisted at a significantly reduced level (29.1-34.4% of baseline).
Conclusions:
- Parlodel is an effective treatment for pituitary macroprolactinoma, achieving hormonal normalization and restoring fertility.
- Intermittent, ovulation-targeted dosing may be a viable strategy for managing hyperprolactinemia and facilitating conception.
- Long-term management may be necessary, even after successful pregnancy, to control residual hyperprolactinemia.